TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (Nasdaq:CGEN) today announced that it has retained Porter Novelli Life Sciences to design and execute an investor and public relations campaign to achieve greater recognition of Compugen’s accelerating commercial progress and broadly applicable drug and diagnostic discovery capabilities in the U.S. financial and media communities.
